Latest Content

New ASCO data show a TNBC drug combo works for nearly all patients no matter their tumor's genetic profile.

FDA approves Welireg plus Keytruda for adults with high-risk renal cell carcinoma following nephrectomy based on phase 3 LITESPARK-022 trial results

New data show a leukemia treatment working better in real patients than expected with response rates nearly double what trials showed. Here's what it could mean for you.

Psychologist Ian Sadler explains why many patients with cancer face anxiety and emotional challenges after treatment ends and why mental health support matters.

Updated COMMANDS trial data show Reblozyl improved survival and long-term transfusion independence vs. Epogen in lower-risk MDS patients.

Early ASCO data show emiltatug ledadotin produced durable responses in patients with aggressive adenoid cystic carcinoma.

Five-year KEYNOTE-942 data show a personalized cancer vaccine plus Keytruda reduced recurrence risk in patients with high-risk melanoma.

Mariska Hargitay discusses her father's myeloma, hope from research and the importance of community and caregivers for patients.

Monjuvi and Revlimid plus R-CHOP helped patients with high-risk diffuse large B-cell lymphoma stay in remission longer and reduce relapse risk.

A survivor reflects on scanxiety, changing follow-up schedules and adapting when a cancer scare disrupted the routine that had brought reassurance.

Dr. John Marshall answers common questions about colorectal cancer, including biomarker testing, treatment options, second opinions and more.

A uterine cancer survivor shares her journey through severe bleeding, emergency surgery, daily radiation treatments, and managing post-chemo GI issues.

A survivor shares her personal journey with stage 2A breast cancer, from choosing a bilateral mastectomy to navigating chemotherapy and hair loss.